- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study, Treatment
- Study type descriptors: Retrospective, Multicentre
- Objective: To describe the real-world use of sotrovimab, as well as clinical outcomes in a population with assumed treatment with sotrovimab for the management of high-risk patients with COVID-19 in National Health Service hospitals across England
- Number of participants enrolled: 10096
- Study enrolling from to
- Study includes follow-up for 1 month
- Standardisation: ICD-10
Study Data
- Adults
- Elderly
- Fragile population
- Paediatric
- Emergency department
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
External Links
Other information
Funders/Sponsors:
- GSK
- Vir Biotechnology
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to